Repligen Corporation $RGEN Shares Bought by Fred Alger Management LLC

Fred Alger Management LLC boosted its position in shares of Repligen Corporation (NASDAQ:RGEN) by 154.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 911,527 shares of the biotechnology company’s stock after buying an additional 553,105 shares during the quarter. Fred Alger Management LLC owned approximately 1.62% of Repligen worth $149,363,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Iron Triangle Partners LP acquired a new stake in shares of Repligen during the third quarter valued at about $36,091,000. Hudson Bay Capital Management LP acquired a new stake in shares of Repligen during the third quarter valued at about $2,807,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Repligen during the fourth quarter valued at about $199,176,000. Cinctive Capital Management LP acquired a new stake in shares of Repligen during the third quarter valued at about $3,398,000. Finally, Royce & Associates LP increased its position in shares of Repligen by 66.1% during the third quarter. Royce & Associates LP now owns 148,658 shares of the biotechnology company’s stock valued at $19,871,000 after acquiring an additional 59,136 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 0.6%

Shares of RGEN stock opened at $131.69 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock has a market capitalization of $7.43 billion, a P/E ratio of 146.32, a price-to-earnings-growth ratio of 2.52 and a beta of 1.09. The company has a 50 day moving average price of $120.77 and a 200 day moving average price of $137.13. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts predict that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RGEN shares. HSBC dropped their price target on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. HC Wainwright lifted their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.